Anti-Vaginolysin [9B4]

Absolute Antibody

Anti-Vaginolysin [9B4]

7

The antibody binds to VLY with an affinity (Kd) of 0.29 nM and an IC50 of 0.067 nM (determined by hemolytic assay). The antibody has a strong neutralizing capability.

The antibody binds specifically to VLY, a pore-forming toxic member of the cholesterol-dependent cytolysins, produced by the bacterium Gardnerella vaginalis. Once released, VLY acts by binding to cholesterol-rich membranes and forming transmembrane pores that result in lysis of the cell. The bacterium G. vaginalis is predominant in the vaginal tract of women with bacterial vaginosis (BV). Here releases VLY toxins that cause cytolysis and tissue destruction, and potentially leading to serious adverse effects such as infertility. Antibodies that are able to neutralize the toxic activity of VLY can be used as therapeutic agents for the treatment of BV. The antibody 9B4 has the strongest neutralizing activity, and binds to an epitope region comprising of the amino acids 122 to 268 of VLY.

Western Blot, ELISA, Neutralisation/Blocking

ELISA; WB; Block

Research Use Only

Monoclonal

9B4

Mouse

IgG1

Bacteria

G. vaginalis

Recombinant VLY.

-20°C,2°C to 8°C

12352203